<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1661">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02133300</url>
  </required_header>
  <id_info>
    <org_study_id>u0064027</org_study_id>
    <nct_id>NCT02133300</nct_id>
  </id_info>
  <brief_title>NMES in Critically Ill Patients</brief_title>
  <acronym>NESCI</acronym>
  <official_title>Neuromuscular Electrical Stimulation in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Katholieke Universiteit Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Katholieke Universiteit Leuven</source>
  <oversight_info>
    <authority>Belgium: Catholic University Leuven</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Critically ill patients with a predicted prolonged ICU stay will receive neuromuscular
      electrical stimulation (NMES) of one quadriceps muscle. Whether the dominant or non-dominant
      side will be stimulated is chosen randomly by using opaque sealed envelopes. The patients
      will receive electrical stimulation for 1h for 7 consecutive days. The stimulated and
      non-stimulated side will be compared for it's thickness (by using ultrasound imaging),
      muscle strength if the patients are awake and cooperative (using the medical research
      council scale and handheld dynamometry) and a muscle biopsy will be taken. As a primary
      outcome the investigators hypothesize that electrical stimulation will preserve muscle mass
      with respect to the non-stimulated quadriceps. As secondary outcomes the investigators
      hypothesize that electrical stimulation can reduce muscle strength loss and leads to a
      better protein balance and thicker muscle fibers in the stimulated quadriceps.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2014</start_date>
  <primary_completion_date type="Anticipated">May 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Outcomes Assessor), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Muscle thickness</measure>
    <time_frame>pre-intervention period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ultrasound measure in cm</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Muscle thickness</measure>
    <time_frame>post intervention period</time_frame>
    <safety_issue>No</safety_issue>
    <description>Ultrasound measure in cm</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Muscle strength (MRC &amp; HHD)</measure>
    <time_frame>pre intervention period</time_frame>
    <safety_issue>No</safety_issue>
    <description>MRC: scale HHD: MicroFet, in kg Force</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle fiber thickness</measure>
    <time_frame>post intervention period</time_frame>
    <safety_issue>No</safety_issue>
    <description>biopsy using Bergström-Stille 5mm needles</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Muscle strength (MRC &amp; HHD)</measure>
    <time_frame>post intervention period</time_frame>
    <safety_issue>No</safety_issue>
    <description>MRC: scale HHD: MicroFET, in kg Force</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Protein balance</measure>
    <time_frame>post intervention</time_frame>
    <safety_issue>No</safety_issue>
    <description>biopsy using Bergström-Stille 5mm needles</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">90</enrollment>
  <condition>Critically Ill Patients With a Predicted Prolonged ICU Stay</condition>
  <arm_group>
    <arm_group_label>electrical stimulation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Compex 3 professional NMES for 60' per day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>electrical stimulation</intervention_name>
    <arm_group_label>electrical stimulation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All adult ICU patients with a predicted prolonged ICU stay

        Exclusion Criteria:

          -  Preexisting neuromuscular disease, polyneuropathy or myopathy (e.g. Guillain-Barré,
             myasthenia gravis, Amyotrophic Lateral Sclerosis, paraplegia, multiple sclerosis, …)

          -  Receiving neuromuscular blocking agents

          -  Musculoskeletal conditions of the pelvis and/or lower limb (e.g. fractures, skin
             disease )

          -  Focal neurological conditions of the pelvis and/or lower limb

          -  Skin disease (e.g. burns)

          -  Presence of a pace-maker or defibrillator

          -  Hemodynamic or Respiratory Instability, active cardiac ischemia

          -  High fever (&gt;39°)

          -  Pregnancy

          -  Brain death

          -  Intracranial pressure &gt;20 mmHg

          -  An anticipated fatal outcome

          -  Psychiatric disorders or severe agitation

          -  Re-admission to the ICU
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University Hospitals Leuven</name>
      <address>
        <city>Leuven</city>
        <state>Vlaams-Brabant</state>
        <zip>3001</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Segers, MSc</last_name>
      <phone>+3216342356</phone>
      <email>johan.segers@faber.kuleuven.be</email>
    </contact>
    <investigator>
      <last_name>Johan Segers, MSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Rik Gosselink, PhD, PT</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Greet Hermans, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Ilse Vanhorebeek, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>June 2014</verification_date>
  <lastchanged_date>June 4, 2014</lastchanged_date>
  <firstreceived_date>May 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Katholieke Universiteit Leuven</investigator_affiliation>
    <investigator_full_name>Johan Segers</investigator_full_name>
    <investigator_title>M.Sc.</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Critical Illness</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
